Protein Catalyzed Capture Agents (PCCs)
We pioneered a new class of synthetic molecules called protein catalyzed capture agents (PCC) that bind proteins like antibodies but exhibit high stabilities and can be rapidly produced at low costs.
The development of personalized therapies is an outstanding challenge in cancer immunology. Our group is focused on developing technologies to identify and elucidate CD8+ T cells, which are key to o adoptive cell therapies and vaccines.
Predicting Cancer Therapy
We are developing single cell proteomics and single cell metabolomics methods that, when combined with kinetic studies and statistical physics models, can yield effective cancer treatment strategies for individual patients, and can unveil mechanisms of drug response and resistance.